Dr. Eggener’s research and clinical interests focus on improving the management and outcomes for patients with localized prostate cancer with specific emphasis on active surveillance, focal therapy and optimizing surgical outcomes. He has published extensively on prostate cancer with 75 peer-reviewed publications and multiple on PSA screening, surgery, prostate imaging, active surveillance or focal therapy for prostate cancer. He is on the editorial board of four journals, including Prostate Cancer and Prostatic Diseases.
Memorial Sloan-Kettering Cancer Center
New York
Urologic oncology fellowship
Northwestern Memorial Hospital
Chicago
General and urologic surgery internship and residency
Standford University School of Medicine
California
MD
Genomic Classifiers To Guide Postprostatectomy Radiation Therapy: An Opening Movement in G-MINOR.
Genomic Classifiers To Guide Postprostatectomy Radiation Therapy: An Opening Movement in G-MINOR. Eur Urol. 2024 Nov 29.
PMID: 39616001
Projected Outcomes of Reduced-Biopsy Management of Grade Group 1 Prostate Cancer: Implications for Relabeling.
Projected Outcomes of Reduced-Biopsy Management of Grade Group 1 Prostate Cancer: Implications for Relabeling. J Natl Cancer Inst. 2024 Nov 20.
PMID: 39565901
Oncological Outcomes Following Robotic Postchemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer: A Worldwide Multicenter Study.
Oncological Outcomes Following Robotic Postchemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer: A Worldwide Multicenter Study. Eur Urol Focus. 2024 Nov 16.
PMID: 39551650
Primary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma.
Primary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma. Clin Transl Radiat Oncol. 2024 Nov; 49:100879.
PMID: 39529961
Quantitative Multi-Parametric MRI of the Prostate Reveals Racial Differences.
Quantitative Multi-Parametric MRI of the Prostate Reveals Racial Differences. Cancers (Basel). 2024 Oct 16; 16(20).
PMID: 39456593
Prostate cancer and solid organ transplantation: patient management and outcomes.
Prostate cancer and solid organ transplantation: patient management and outcomes. BJU Int. 2024 Oct 09.
PMID: 39385314
When is prostate cancer really cancer?
When is prostate cancer really cancer? J Natl Cancer Inst. 2024 Oct 01.
PMID: 39350309
Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves cross-ancestry prediction.
Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves cross-ancestry prediction. medRxiv. 2024 Aug 20.
PMID: 37961155
Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial.
Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial. J Clin Oncol. 2024 Nov 10; 42(32):3806-3816.
PMID: 39038251
Overcoming the Code Duello: Achieving Long-term Cure and Optimizing Quality of Life in Testicular Cancer.
Overcoming the Code Duello: Achieving Long-term Cure and Optimizing Quality of Life in Testicular Cancer. Eur Urol Focus. 2024 May; 10(3):355-356.
PMID: 39013684